MassHealth does cover Zepbound right now, but only through prior authorization and only until July 2, 2026. Starting July 3, 2026, MassHealth will stop paying for Zepbound or any other medication prescribed solely for weight loss. Coverage will continue past that date only for a narrow set of medical conditions, and even then Wegovy becomes the preferred drug while Zepbound moves to non-preferred status.
What MassHealth Covers Today
Zepbound is currently listed as a preferred drug on the MassHealth Drug List, and every prescription requires prior authorization.1MassHealth Drug List. Anti-Obesity Agents Therapeutic Class Detail To be approved, you must be at least 18 and have a documented diagnosis of obesity or overweight. Your prescriber must record your weight within 90 days of starting the medication and confirm that you have been counseled on a reduced-calorie diet and increased physical activity.
The BMI you need depends on what other conditions you have:
- BMI of 35 or higher, with no other condition required.
- BMI of 30 or higher, together with heart failure with preserved ejection fraction, uncontrolled hypertension, chronic kidney disease stage 3a or above, or moderate-to-severe obstructive sleep apnea.
- BMI of 27 or higher, together with pre-diabetes, a history of heart attack or stroke, noncirrhotic MASH with stage F2–F3 fibrosis, symptomatic peripheral artery disease, or type 2 diabetes.
Zepbound is limited to four pens per 28 days, and you cannot take it at the same time as another GLP-1 receptor agonist.1MassHealth Drug List. Anti-Obesity Agents Therapeutic Class Detail
One recertification detail catches many people off guard. MassHealth updated its rules in February 2026, and to keep receiving Zepbound you now have to show documented progress: at least 5% weight loss from baseline, improvement in blood pressure or blood glucose linked to the therapy, improvement in sleep apnea symptoms, or a clinical need for cardiovascular risk reduction. Eligibility at recertification is judged against your BMI before you started any GLP-1, not your current weight. Members who have lost significant weight can still be denied continuation if that original BMI no longer meets the threshold for their comorbid conditions.1MassHealth Drug List. Anti-Obesity Agents Therapeutic Class Detail
What Changes on July 3, 2026
On July 3, 2026, MassHealth stops paying for any medication prescribed solely to treat obesity or overweight.2Massachusetts Executive Office of Health and Human Services. Pharmacy Facts, Issue 5, March 2026 That includes Zepbound, Wegovy, Saxenda, Qsymia, Contrave, phentermine formulations, orlistat, and other weight-loss drugs. Off-label use of any medication for weight loss is also excluded.3Massachusetts Executive Office of Health and Human Services. Pharmacy Facts, Issue 7, May 2026
If your prior authorization for an anti-obesity medication was submitted before February 17, 2026, it is being end-dated on July 2, 2026. Your provider will need to submit a new request if you qualify under the revised criteria.2Massachusetts Executive Office of Health and Human Services. Pharmacy Facts, Issue 5, March 2026
Conditions That Still Qualify After July 2026
MassHealth will keep covering GLP-1 and GIP/GLP-1 medications for a defined list of medical indications after the cutoff. Wegovy becomes the sole preferred drug for these uses, and Zepbound is available only as a non-preferred alternative after a documented trial of Wegovy.3Massachusetts Executive Office of Health and Human Services. Pharmacy Facts, Issue 7, May 2026 The qualifying conditions are:
- Cardiovascular disease with a BMI above 27, to reduce the risk of major adverse cardiovascular events.
- Moderate-to-severe obstructive sleep apnea with a BMI above 30.
- Metabolic dysfunction-associated steatohepatitis (MASH), with no specific BMI requirement.
- Members under 21, evaluated for medical necessity under federal Early and Periodic Screening, Diagnostic, and Treatment rules.
For members under 21 who are new to GLP-1 therapy, Mass General Brigham Health Plan’s guidance indicates a step-through trial of both phentermine and Wegovy may be required before Zepbound is authorized.4Mass General Brigham Health Plan. Formulary Updates, May 2026
Options If You Lose Coverage
If you take Zepbound for weight loss and don’t fit one of the surviving indications, you have a few realistic paths.
Switch to a diabetes GLP-1 if you qualify. Members with type 2 diabetes or prediabetes can move to a GLP-1 approved for that condition. Mounjaro contains the same active ingredient as Zepbound at the same doses and remains a preferred MassHealth drug for type 2 diabetes.5MassHealth Drug List. Antidiabetic Agents GIP and GLP-1 Agonist Therapeutic Class Detail An October 2025 MassHealth bulletin noted that patients with both diabetes and obesity who newly request Zepbound must step through Mounjaro first, because the two drugs are chemically identical.6Massachusetts Executive Office of Health and Human Services. Pharmacy Facts, Issue 12, August 2025
Get switched to Wegovy automatically. If you have an approved Zepbound authorization extending past July 2, 2026, and you qualify under one of the remaining covered indications, MassHealth will replace it with an approved Wegovy authorization for the rest of the original period. Your provider then writes a new prescription for Wegovy.3Massachusetts Executive Office of Health and Human Services. Pharmacy Facts, Issue 7, May 2026
Pay out of pocket. Zepbound runs up to roughly $450 per month at full cost according to WBUR reporting.7WBUR. Mass Cutting GLP-1 Coverage Medicaid Wegovy Zepbound Some patients have reported taking on extra work or drawing from savings to cover it.
Use Vida Health for non-drug support. MassHealth’s Vida Health program continues through the end of 2026, offering weight management coaching, behavioral support, and consultations with registered dietitians. It will no longer prescribe GLP-1s or other anti-obesity medications, but Vida staff will help members find direct-pay options.8Massachusetts Executive Office of Health and Human Services. April Update on Vida Health Program and GLP-1 Coverage
How Your Managed Care Plan Handles This
MassHealth delivers most coverage through managed care organizations, and the plan you’re in changes the details.
Point32Health, which runs Tufts Health Together, Tufts Health Senior Care Options, and Tufts Health One Care, ends coverage of all anti-obesity agents for weight loss on July 1, 2026. Under Tufts Health Together, Zepbound loses preferred status entirely, and any continued authorization requires a documented trial of Wegovy first. Members with diabetes or prediabetes are directed to a diabetic GLP-1 such as Ozempic or Mounjaro.9Point32Health. MassHealth Coverage Change Anti-Obesity Medications
UnitedHealthcare Community Plan of Massachusetts is implementing the same restrictions on July 1, 2026, ending coverage of a dozen weight-loss medications including Zepbound. Coverage continues for diabetes, cardiovascular disease, and obstructive sleep apnea, but providers must submit a new prior authorization if none is already in place for the non-weight-loss indication.10UnitedHealthcare. MA Medicaid Weight and Obesity Drug Coverage
WellSense Health Plan moved earlier on its Massachusetts Clarity product line, ending weight-loss drug coverage on January 1, 2026.11WellSense Health Plan. Weight Loss Drugs Coverage Communication
Getting Prior Authorization and Appealing a Denial
Every Zepbound prescription needs prior authorization, whether under the current weight-loss criteria or the post-July medical indications. The route depends on how you’re enrolled.
For fee-for-service MassHealth, the prescriber finds the correct form on the MassHealth Drug List website by searching for the drug or browsing the anti-obesity agents therapeutic class. Completed forms go to the MassHealth Drug Utilization Review Program by fax at (877) 208-7428 or by mail to P.O. Box 2586, Worcester, MA 01613-2586. The program’s phone line is (800) 745-7318.12Massachusetts Executive Office of Health and Human Services. Request a Prior Authorization for a Drug Members in managed care plans submit through their plan’s portal: CoverMyMeds for Fallon Health and Health New England, the Point32Health Provider Portal for Tufts plans, and the WellSense Provider Portal for WellSense members.13MassHealth Drug List. Prior Authorization Forms for Pharmacy Services
If your prior authorization is denied, you have the right to a fair hearing. In a managed care plan, you must exhaust the plan’s internal appeal first before requesting a state-level hearing. To file, submit the appeal form included with your denial notice by mail, by fax to 617-887-8797, or by email to boh-fairhearingsrequest@mass.gov. You can also call MassHealth Customer Service at (800) 841-2900 for help filing by phone. The appeal must be received within 60 days of the denial notice.14Massachusetts Legal Services. Troubleshooting and Appeals
One detail matters more than the others. To keep receiving the medication while your appeal is pending, you have to file within 10 days of receiving the denial notice and explicitly request “aid pending” on the form. Hearings are usually conducted by phone, and they are a fresh review, so you can submit additional medical records or testimony that were not part of the original prior authorization request.14Massachusetts Legal Services. Troubleshooting and Appeals